Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on June 22, 2020. The Company is a Nevada corporation with principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The NASDAQ Stock Market LLC under the symbols "XBIO" and "XBIOW," respectively.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
The primary event reported is the resolution of a listing deficiency:
- Prior Status: On April 20, 2020, the Company received notification from Nasdaq that it was non-compliant with the minimum bid price requirement under Listing Rule 5550(a)(2).
- Resolution: On June 22, 2020, Nasdaq notified the Company that it has regained compliance.
- Compliance Criteria Met: The closing bid price of the Company's common stock was at least $1.00 per share for 10 consecutive business days from June 8, 2020, through June 19, 2020.
- Current Status: The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific listing compliance issue addressed in Item 8.01.
Key Facts for Investor Verification
- Verify the current trading price of XBIO to ensure continued compliance with Nasdaq's minimum bid price requirement.
- Confirm that the Company has not received any new deficiency notices from Nasdaq subsequent to June 22, 2020.
- Note that this filing provides no update on the Company's operational progress, cash position, or clinical trial status.